Send to

Choose Destination
Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21.

A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder.

Author information

Ahmad Ghanizadeh, M.D., Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, School of Medicine, Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Hafez Hospital, Shiraz, and Department of Psychiatry, Shiraz University of Medical Sciences, School of Medicine, Hafez Hospital , Shiraz , Iran.



No published systematic review has ever assessed the efficacy and safety of reboxetine for treating of patients with attention deficit hyperactivity disorder (ADHD).


This systematic review aimed to review the available evidence regarding the efficacy of reboxetine for treating ADHD.


The databases of Pubmed/Medline, Google scholar, SCOPUS and Web of Science were searched using the Keywords: "reboxetine", "ADHD" and "attention deficit hyperactivity disorder". The reference lists of the included studies were screened to find any possible other relevant articles. All the non-controlled and controlled clinical trials were included.


The current evidence mainly consists of un-controlled studies, such as case series. Only three of 33 studies were controlled clinical trials. They are from single sites and included a sub-sample of patients with ADHD.


Non-controlled studies and controlled trials support the promising effect of reboxetine for treating ADHD in a sub-sample of patients that are without co-morbid psychiatric disorder and mental retardation. Reboxetine is tolerated well. However, more controlled trials are needed to reach any firm conclusion.


Adolescents; Attention deficit hyperactivity disorder; Children; Clinical trial; Reboxetine; Treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center